4.2 Review

The Involvement of miRNAs in Pituitary Adenomas Pathogenesis and the Clinical Implications

Journal

EUROPEAN NEUROLOGY
Volume 85, Issue 3, Pages 171-176

Publisher

KARGER
DOI: 10.1159/000521388

Keywords

MicroRNAs; Pituitary adenoma; Biomarker; Drug resistance; Diagnosis

Ask authors/readers for more resources

Pituitary adenomas (PAs) are among the most common primary intracranial tumors, causing severe endocrine disorders and malignant features. miRNAs play important roles in the invasion and metastasis of PAs and have been extensively studied as potential screening or prognostic biomarkers. This review summarizes recent studies on the emerging roles of miRNAs in PAs and their clinical significance.
Pituitary adenomas (PAs) account for the top three primary intracranial tumors in terms of total incidence rate. PAs can cause severe endocrine disorders and even malignant features, such as invasion, metastasis, and recurrence. Therefore, the early diagnosis and accurate prognosis would be greatly beneficial for clinical treatment of PAs. MicroRNAs (miRNAs) are small, protein-noncoding RNAs that regulate gene expression posttranscriptionally. They regulate essential physiological processes, including proliferation, growth, and apoptosis, and also they involve in the invasion and metastasis of malignant tumors. At the tissue level, differential miRNA expression in endocrine malignancies including PAs has been reported. When miRNAs have been successfully detected in various biofluids and cell-free environments, their important roles as potential screening or prognostic biomarkers have been extensively investigated. The current work reviews recent studies on the emerging roles of miRNAs in PAs and the clinical significance.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available